Fiona Stevens

Could the new EU Medical Devices Regulation put the UK MedTech industry in peril?

There has been much debate in recent years about the difficulty in attracting both private and public funds into the UK biotech industry.  At certain points, it seemed like a disproportionate percentage of the funding that was invested into UK biotech came from the US.  It is likely that there...

Read more

UK Supreme Court judgment in long-running dispute between Eli Lilly and Actavis on the combination therapy pemetrexed + vitamin B12 results in significant outcomes for patent infringement in the UK

In a judgment issued on 12 July, the UK Supreme Court made some significant changes in the law of UK patent infringement which could have far reaching consequences, especially in the pharmaceutical sector. In particular, they addressed the issue of infringement by equivalents not otherwise falling within the literal claim scope and...

Read more

The Importance of IP Due Diligence in M&A and Investment Transactions

Due diligence plays a central role in any M&A or investment transaction and its importance in guiding the transaction cannot be over stated. Fiona Stevens, a partner in GJE’s Life Sciences team who frequently advises on the intellectual property aspects of commercial transactions, discusses the importance of IP due diligence....

Read more

The never-ending debate on the value of second medical use patents

It is well established that a second medical use patent may be validly obtained in Europe for any second or further therapeutic use of a known drug, providing the use is novel and inventive. However, it can be difficult to enforce a second medical use patent if the drug is...

Read more